<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
58468-0347-1
</NDCCode>
<PackageDescription>
1 VIAL in 1 CARTON (58468-0347-1) / .2 mL in 1 VIAL
</PackageDescription>
<NDC11Code>
58468-0347-01
</NDC11Code>
<ProductNDC>
58468-0347
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Qfitlia
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Fitusiran
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20250328
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA219019
</ApplicationNumber>
<LabelerName>
Genzyme Corporation
</LabelerName>
<SubstanceName>
FITUSIRAN
</SubstanceName>
<StrengthNumber>
20
</StrengthNumber>
<StrengthUnit>
mg/.2mL
</StrengthUnit>
<Pharm_Classes>
Antithrombin-directed RNA Interaction [EPC], Decreased RNA Integrity [PE], Increased RNA Degradation [PE], RNA, Small Interfering [CS], Small Interfering RNA [EPC]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2025-09-17
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20250328
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>